Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial-Reference-Cited by-同舟云学术

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

Published:2023-04-05 Issue:1 Volume:34 Page:
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Thyssen Jacob P.¹,Werfel Thomas²,Barbarot Sebastien³,Hunter Hamish J.A⁴,Pierce Evangeline⁵,Sun Luna⁵,Cirri Lisa⁵,Buchanan Andrew S.⁵,Lu Na⁶,Wollenberg Andreas⁷

Affiliation:

1. Department of Dermatology and Venersology, Bispebjerg Hospital, Copenhagen, Denmark

2. Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

3. Department of Dermatology, Nantes Université, Centre Hospitalier Universitaire de Nantes, Nantes, France

4. Department of Dermatology, Salford Care Organisation, part of the Northern Care Alliance NHS Foundation Trust, Salford, UK

5. Eli Lilly and Company, Indianapolis, IN, USA

6. Precision Statistics Consulting, Woodbury, MN, USA

7. Department of Dermatology and Allergy, University Hospital, Ludwig Maximillian University, Munich, Germany

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2023.2190430

Reference46 articles.

1. Impact of disease severity on sleep quality in Japanese patients with atopic dermatitis

2. Specific T cells targeting Staphylococcus aureus fibronectin‐binding protein 1 induce a type 2/type 1 inflammatory response in sensitized atopic dermatitis patients

3. Burden of skin pain in atopic dermatitis

4. Comorbidities and the impact of atopic dermatitis

5. Epidemiology of adult atopic dermatitis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks;Dermatology and Therapy;2024-07-13

2. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions;Molecules;2023-12-13

3. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores;Journal of the European Academy of Dermatology and Venereology;2023-12-02

4. Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis;Expert Opinion on Pharmacotherapy;2023-11-29

5. [Translated article] Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives;Actas Dermo-Sifiliográficas;2023-09